Growth and change of COVID-19 until 2030


The major players in the current Coronavirus Therapy (COVID-19) market are Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., Biocryst Pharma, Gilead Sciences and Regeneron Pharmaceuticals.

New York, September 27, 2021 (GLOBE NEWSWIRE) – announces the publication of the report “Coronavirus (COVID-19) Current Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030” – https: / / www.

The global coronavirus (COVID-19) therapies market is expected to grow from $ 14.63 billion in 2020 to $ 16.8 billion in 2021 at a compound annual growth rate (CAGR) of 14.8%. The growth is primarily driven by businesses resuming operations and adjusting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive containment measures involving social distancing, the remote work and closure of business activities which resulted in operational challenges. The market is expected to reach $ 35.42 billion in 2025 at a CAGR of 20%.

The current coronavirus (COVID-19) therapy market includes sales of drugs currently in use for the treatment of COVID-19 infection.

The market consists of the revenue generated by companies that manufacture current coronavirus therapeutics through the sale of these products.

The Current Coronavirus (COVID-19) Therapeutics market covered in this report is segmented by drug type into Antivirals (Remdesivir, Ritonavir, Lopinavir), Antimalarials (Hydroxychloroquine), Interferons (Interferon Beta), Corticosteroids (dexamethasone), Others and by end-use in hospitals, clinics, research institutes, others.

The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East & Africa.

The high costs involved in the research and development of therapeutic drugs and vaccines and the long wait time required for each phase of clinical trials are expected to limit the growth of the current coronavirus (COVID-19) therapy market. According to a recent study published in the Journal of Health Economics by the Tufts Center for the Study of Drug Development, developing a new prescription drug and obtaining market authorization would cost $ 2.6 billion. dollars. the development process. In addition, the time required for each phase of the clinical trial and drug approval process takes an average of 12 years for an investigational drug to reach the market. High costs and long wait times for drug development are expected to hamper the current coronavirus (COVID-19) therapy market.

In March 2020, Sanofi and Regeneron Pharmaceuticals are scheduled to launch clinical trials of the rheumatoid arthritis drug Kevzara (sarilumab) for the treatment of symptoms of COVID-19. The United States Food and Drug Administration (FDA) approved Kevzara in 2017 to treat rheumatoid arthritis.

The drug is part of an ongoing antibody partnership between Sanofi and Regeneron. Kevzara is a fully human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor.

IL-6 may play a role in driving the overactive inflammatory response in the lungs of critically or critically ill patients with COVID-19. Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately modified so that only critical patients continue to be recruited to receive Kevzara 400 mg.

The outbreak of the COVID-19 pandemic has contributed to the growth of the current coronavirus therapy (COVID-19) market. On March 11, 2020, the World Health Organization (WHO) declared the epidemic a global pandemic.

According to the World Health Organization (WHO), 10,719,946 cases of COVID-19, including 517,337 deaths, have been reported to the WHO as of July 3, 2020, and that number is expected to increase soon. Since there is no officially approved drug for COVID-19, the demand has dramatically increased for reused drugs that are used for corona therapy.

Countries around the world are facing drug shortages and drug manufacturers are increasing production to meet global demand. The Coronavirus Treatment Acceleration Program (CTAP) is a special emergency program initiated by the FDA for the development of potential COVID-19 therapies to be made available to patients as quickly as possible.

Convalescent plasma therapy is being used as an experimental therapy to treat COVID-19 patients. The blood plasma of patients who have recovered from illness is called convalescent plasma (CP).

Convalescent plasma therapy (CP) is a type of passive antibody therapy in which blood plasma is isolated from patients who have recovered from the disease of interest and administered to the patient with severe disease to suppress virulence and improve clinical symptoms. Blood plasma from recovered COVID-19 patients have antibodies to fight the COVID-19 infection.

According to guidelines issued by the FDA, convalescent plasma therapy is recommended as an investigational product during a public health emergency. As of April 30, 2020, approximately 2,004 participating sites adhering to a single U.S. FDA Extended Access Protocol have been registered, approximately 7,774 patients have enrolled and 3,809 of these have undergone convalescent plasma transfusion.

Experimental convalescent plasma therapy is likely to attract attention if enough data to support the results.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, United Kingdom and United States.
Read the full report:

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Source link


Leave A Reply